Glaucoma changes rapid contrast adaptation

Article

Glaucoma, but not ageing, changes rapid contrast adaptation, which is vital to visual processing in natural visual environments, say researchers from Australia in a recent study.

Glaucoma, but not ageing, changes rapid contrast adaptation, which is vital to visual processing in natural visual environments, say researchers from Australia in a recent study. "Our results imply that glaucoma produces abnormalities in natural visual experiences in central vision," they write.

Their study included 14 people with glaucoma, 17 age-similar controls, and 19 younger adults. The investigators measured contrast detection and discrimination thresholds in central vision for briefly presented Gabor patches with and without adaptation to 50% contrast Gabor patches. They measured detection thresholds at 47, 106, 200, 400, 600 and 1000 msecs adaptation, and they measured discrimination thresholds after adaptation relative to a reference contrast below, equivalent to, or above the adaptor.

The unadapted detection and discrimination thresholds were elevated in those in the glaucoma group compared with the age-similar controls, the authors found. Ageing elevated unadapted thresholds in normal observers. At 47 msecs after adaptation, those in the glaucoma group experienced reduced effects of adaptation relative to those in the control group. Adaptation was also reduced when the reference contrast was equivalent to the adaptor. Ageing, however, did not change adaptation in normal observers.

To read an abstract of the study, visit the journal

Investigative Ophthalmology and Visual Science

.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.